Estradiol (E2) and blood glucose are linked through several physiological mechanisms. Estradiol enhances insulin sensitivity by promoting GLUT4 translocation in muscle and adipose tissue and by suppressing hepatic glucose production. Premenopausal women typically exhibit better insulin sensitivity than men. After menopause, declining estradiol levels contribute to increased insulin resistance and higher fasting glucose. In conditions like PCOS, relative estrogen excess is associated with insulin resistance, though causality is complex. Evidence comes mainly from observational studies and mechanistic research; randomized trials on estradiol therapy show modest improvements in glucose homeostasis, but effects vary. Hormone replacement therapy should not be used solely for blood sugar control due to risks (thrombosis, breast cancer). In summary, estradiol influences blood sugar, but the effect is moderate and context-dependent. Direct clinical recommendations for glucose management based solely on estradiol levels are not evidence-based.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-d60b43fe3cf84ad4b0beb8fc